|drug1546||Flexitouch Plus with Cellular Connectivity (FT-CC) Wiki||0.71|
|D000072656||Breast Cancer Lymphedema NIH||0.71|
|D001943||Breast Neoplasms NIH||0.29|
There are 2 clinical trials
The objective of this study is to demonstrate the feasibility of using the Flexitouch Plus with Cellular Connectivity (FT-CC) to monitor device use data to determine if reminders to patients impact compliance, and to identify the impact device compliance has on arm girth, quality of life (QOL), and symptom assessment.
Description: Compare the rate of compliance (defined as the number of days device used/total study days) in patients treated with PASSIVE FT-CC and ACTIVE FT-CC.Measure: Compliance Time: Changes between 30 days after device training and 60 days after device training
Description: Comparison of partially compliant and compliant arm girth in patients treated with FT-CC. Arm girth is measured in cm.Measure: Change in Arm Girth Time: Changes between baseline, 30 days after device training, and 60 days after device training
Description: Comparison of partially compliant and compliant quality of life in patients treated with FT-CC via Lymphedema Quality of Life Tool (LYMQOL ARM). Lymphedema Quality of Life Tool (LYMQOL-ARM) includes sub-scores for Function (range 10-40), Appearance (range 5-20), Symptoms (range 6-24), and Emotion (range 6-24) where lower scores represent a better outcome. It also includes an Overall QOL sub-score (range 0-10) where a higher score represents a better outcome.Measure: Quality of Life Assessment via LYMQOL ARM Time: Changes between baseline, 30 days after device training, and 60 days after device training
Description: Comparison of partially compliant and compliant quality of life in patients treated with FT-CC by via The RAND 36-Item Short Form Survey (SF-36). The RAND 36-Item Short Form Survey (SF-36) taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item for perceived change in health. Min value: 0, Max value: 100. Higher scores represent a better outcome.Measure: Quality of Life Assessment via SF-36 Time: Changes between baseline, 30 days after device training, and 60 days after device training
Description: Comparison of partially compliant and compliant symptoms in patients treated with FT-CC by via The Lymphedema Symptom Intensity and Distress Survey-ARM (LSIDS-A). The Lymphedema Symptom Intensity and Distress Survey is a questionnaire used to assess intensity and distress of symptoms in patients with lymphedema of the arm. This includes sub-scores for soft tissue sensation (range 0-10), neurological sensation (0-10), function, (0-10), biobehavioral (0-10), resource (0-10), sexuality (0-10), activity (0-10). Higher score represents worse outcome.Measure: Symptoms Assessment via LSIDS-A Time: Changes between baseline, 30 days after device training, and 60 days after device training
The pandemic, which started in China at the end of 2019, appeared in our country in a short time. Most hospitals and physicians were only concerned with the treatment of these patients. One of the most victimized patient groups in this duration was lymphedema patients who were in need of continuous follow-up and rehabilitation at necessary periods, but were also at risk in terms of covid-19 infection and could not go to hospitals unless necessary. The treatment of both primary and secondary lymphedema patients has been interrupted or delayed. This process has affected the health status, treatment processes and quality of life of the lymphedema patient group. The current situation may have caused them anxiety and depression as a result of infection fear. In this study, we aimed to evaluate the treatment processes, health status, coronavirus phobia, anxiety, and depression states of the lymphedema patients .
Description: The CP19-S has 20 items which is a self-report instrument with a five-point Likert-type scale to assess the levels of coronavirus (covid-19) phobia. All items are rated on a 5 point scale from "strongly disagree (1)" to "strongly agree (5)." The scores on the scale can range between 20 and 100 and a higher score indicates a greater phobia in the respected subscales (psychological, psycho-somatic, economic and social) and total scale. In the present study total scale scores ranged from 20 to 100 .Measure: Coronavirus Phobia Scale Time: 1 day
Description: The LYMQOL-Arm consists of four domains with 28 items. These domains are symptoms, appearance, function, and mood. The answers were evaluated on a four-point Likert scale (1= not at all 2= a little, 3= quite a bit, 4= a lot). Each item received a score between 1 and 4, with higher scores indicating a worse QOL. Domain totals were calculated by adding the individual scores and dividing the total by the number of questions answered (If >50% of questions per domain were not answered this cannot be calculated *and =0). If the item was not scored and left blank or not applicable, this was scored with a 0. The four domains and their corresponding questions are: Function 1 (a-h), 2,3, Appearance 4,5,6,7,8 Symptoms 9,10,11,12,13,14 and Emotion 15,16,17,18,19,20. Overall QOL (Q21) is scored as the value marked by the patient, between 0-10Measure: Lymphedema Quality of Life Arm Time: 1 day
Description: The LYMQOL-Leg consists of 27 items: 26 multiple-choice questions and 1 rating question. It covers four domains: symptoms, appearance, function, and mood. Scoring and calculating is same with the arm scale but differences are; function 1 (a-f), 2,3 appearance 4,5,6,7,8,9,10 symptoms 11,12,13,14,15 and emotion 16,17,18,19,20,21. Overall quality of life (Q22) is scored as the value marked by the patient, between 0-10.Measure: Lymphedema Quality of Life Leg Time: 1 day
Description: It consists of 14 items with two subscales (seven items for anxiety and seven items for depression). Each item is scored 0-3. Each subscale is scored between 0 and 21. The aim of the scale is not to make a diagnosis, but to determine the risk group bt screening anxiety and depression in a short time in patients with physical diseases. The cut-off points of the Turkish version of the HADS were determined as 10 for the anxiety subscale and 7 for the depression subscale.Measure: Hospital Anxiety and Depression Scale Time: 1 day
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports